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Food supplements that contain glucosamine can constitute a health risk for 
patients who take coumarin anticoagulants as blood coagulation inhibitor  
 
BfR Opinion No. 004/2010, 14 August 2009 
 
Glucosamine is an amino sugar that occurs naturally in human connective tissue, in cartilage 
and synovial fluid. It is used as medicinal product to treat arthrosis of the knee joints. Yet 
glucosamine is also provided in numerous food supplements that are also considered food-
stuffs in intake amounts that are below medicinal dosages. The German authorities for the 
official control of foodstuffs are responsible for controlling the marketability of these sub-
stances. 
 
BfR has already assessed the health risks associated with glucosamine in food supplements 
in a past Opinion1 and identified three risk groups: a) diabetics and/or individuals with im-
paired glucose tolerance, b) patients with a known risk for cardiovascular diseases and c) 
persons who take certain blood coagulation inhibitors known as coumarin anticoagulants. In 
the present Opinion, BfR has once again assessed the health risk for risk groups b) and c). 
This was carried out because these risk groups were not identified as such in a recent Opin-
ion of the European Food Safety Authority (EFSA) on the use of glucosamine as food ingre-
dient.  
 
In regard to the group of individuals with a known risk for cardiovascular diseases, BfR con-
curs with EFSA after a review of the latest research findings. Thus, packages of food sup-
plements that contain glucosamine do not require a notice on the health risks for these con-
sumer groups. 
 
However a repeated assessment has led BfR to continue to classify individuals who take 
coumarin anticoagulants as belonging to a risk group. The Institute has assessed the health 
risks using case studies and concluded that the combined intake of glucosamine with cou-
marin anticoagulants that contain the active substance warfarin or acenocoumarol bears the 
risk of an adverse increase of the anticoagulation effect of coumarin anticoagulants. BfR cur-
rently has no case studies available on the active substance phenprocoumon, which also 
belongs to the group of coumarin anticoagulants. For daily intake amounts of 390-790 milli-
grams of isolated glucosamine in food supplements, BfR deems measures that protect indi-
viduals who take coumarin anticoagulants necessary. The Institute advises consumers who 
take such medication (coumarin anticoagulants) to abstain from consuming food supple-
ments that contain said amounts of isolated glucosamine as daily rations. 
                                                
1 “Verwendung von Glucosamin und dessen Verbindungen in Nahrungsergänzungsmitteln” – “Use of glucosamine and its de-
rivatives in food supplements” (currently only available in German) (BfR, 2007). This BfR Opinion contains a comprehensive 
assessment of glucosmanine by BfR.  
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1   Subject of the assessment 
 
The Federal Institute for Risk Assessment (BfR) already evaluated the risks of food supple-
ments that contain glucosamine in an Opinion in 2007 and referred to risk groups including: 
risks for diabetics, for patients with a known risk for cardiovascular diseases and for individu-
als who take anticoagulants (substances that inhibit blood coagulation). In regard to healthy, 
non-pregnant adults, BfR determined that there are no indications that suggest that the in-
take of glucosamine (as glucosamine sulphate or hydrochloride) below levels of 1250 mg/day 
constitutes a substantial risk (BfR, 2007). 
 
In 2009, the European Food Safety Authority (EFSA) published a Scientific Opinion on the 
safety of glucosamine hydrochloride from Aspergillus niger and reached the conclusion that 
the intake of up to 750 mg glucosamine/day is safe for adults. Diabetics and individuals with 
impaired glucose tolerance should be advised to consult a physician prior to intake (EFSA, 
2009). Risks for individuals who take coumarin anticoagulants and those with a known risk 
for cardiovascular diseases are not mentioned. 
 
BfR has therefore re-evaluated the health risks of individuals who take coumarin anticoagu-
lants and those with a known risk for cardiovascular diseases in regard to food supplements 
with daily intake amounts of 390-790 mg isolated glucosamine/day. 
 
2   Results 
 
In light of possibly severe health related effects of a potential interaction between glucosa-
mine and coumarin anticoagulants, BfR concludes that the use of isolated glucosamine in 
food supplements at intake amounts of 390-790 mg glucosamine/day or more requires 
measures to protect individuals who take coumarin anticoagulants. Potential interactions 
pertain to altered blood coagulation ability possibly resulting in haemorrhage, even subdural 
haematoma (a specific type of cerebral haemorrhage) resulting in a vegetative state. BfR 
recommends that these groups of individuals are excluded from the use of such food sup-
plements. One possible measure to counteract this risk is the use of warning labels on pack-
aging. BfR also deems it legitimate to assess these products as unsafe in terms of Art 14 
Reg. (EC) 178/2002. 
 
Furthermore, the risk for diabetics should be noted (EFSA, 2009; BfR, 2007). 
 
After a review of the present state of research knowledge, BfR has reached the conclusion 
that such warnings for individuals with a known risk for cardiovascular diseases are not nec-
essary for food supplements containing glucosamine if their daily intake amounts are below 
medicinal dosage (below 1250 mg/day). 
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3   Reasons 
 
3.1   Individuals who take coumarin anticoagulants 
  
3.1.1 Hazard potential 
 
Several reports are available concerning possible interactions when coumarin anticoagulants 
are taken together with glucosamine by itself or of warfarin (an active substance from the 
group of coumarins) and a combination of glucosamine and chondroitin sulphate (Yue et al., 
2006; ADRAC/ADRU, 2008; Knudsen & Sokol, 2008; Garcia et al., 2004; Rozenfeld et al., 
2004). Case reports state that when coumarin anticoagulants were taken with glucosamine 
or glucosamine/chondroitin sulphate, changes in the INR value (INR = International Normal-
ised Ratio) were observed. Most often the value increased, while in a few cases it de-
creased. Elevated INR values express decreased blood coagulation ability or an increase of 
the anticoagulant (coagulation inhibiting) effect of coumarin anticoagulants. In this case, 
blood coagulation time is increased in a test procedure. When warfarin was taken together 
with glucosamine (without the simultaneous intake of chondroitin sulphate), elevated INR 
values in some cases occurred in conjunction with haemorrhage, in one case with life-
threatening haemorrhage. 
 
The scientific panel Australian Adverse Drug Reactions Advisory Committee (ADRAC) and 
the Adverse Drug Reaction Unit (ADRU) of the TGA2 reported 12 cases that indicate an in-
teraction between warfarin and glucosamine. In most cases, the increase in INR values was 
asymptomatic. However, in one case, haemorrhage occurred in the anterior chamber of the 
eye and in another case haemoptysis (coughing up or spitting of blood or blood-streaked 
mucus or small amounts of blood from the lungs or respiratory tract) and petechiae (small 
spots of haemorrhaging) occurred (ADRAC/ADRU, 2008). Researchers of the WHO Collabo-
rating Centre for International Drug Monitoring described 22 suspected cases, which in-
cluded nine of the above mentioned Australian cases. In two cases, the intake of glucosa-
mine was combined with that of chondroitin sulphate. Of those cases in which the continuing 
course was known, the INR changes required a doctor’s visit in nine cases and/or hospitali-
sation and/or closer INR value monitoring. In four cases, the adverse interaction required 
hospitalisation or an extension of the hospitalisation and/or treatment with vitamin K. In 17 
out of the 21 cases with elevated INR values, the discontinuation of glucosamine intake was 
connected with a normalisation of INR values (Yue et al., 2006). 
 
Knudsen and Sokol (2008) described a clinical case and identified 20 additional cases of 
potential interactions in the FDA3 MedWatch database, which collected spontaneous cases 
of adverse effects reported by consumers. The publication covers four cases, in which war-
farin was taken together with glucosamine. However it could not be clarified in any of the 
cases whether chondroitin sulphate was also taken. In one of these cases, a person suffered 
from a subdural haematoma resulting in a vegetative state. Furthermore, 16 cases are re-
ported with simultaneous intake of warfarin and a combination of glucosamine and chondro-
itin sulphate, and one case of simultaneous intake of warfarin with chondroitin sulphate. Ad-
ditional cases were reported where the simultaneous intake of warfarin and a combination of 
glucosamine with chondroitin sulphate was associated with decreased blood coagulation 
ability or increased warfarin effects, which sometimes occurred in conjunction with haemor-
rhage or haematoma. Four cases required hospitalisation as a result of blood complications, 
                                                
2 TGA = Therapeutic Goods Administration 
3 FDA = Food and Drug Administration of the United States 
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e.g. one case of gastrointestinal haemorrhage that required blood transfusion and treatment 
with vitamin K or one case of intraventricular haemorrhage (bleeding in cerebral ventricles). 
 
According to researchers at the WHO Collaborating Centre, the close temporal relationship 
between glucosamine intake and increased warfarin effects indicates a possible causality 
(additionally, most of the patients experienced a normalisation/improvement after glucosa-
mine intake was discontinued) (Yue et al., 2006). The researchers concluded that glucosa-
mine could increase the effect of warfarin. Knudson and Sokol (2008) reached a similar con-
clusion. The Australian Adverse Drug Reactions Advisory Committee and the Adverse Drug 
Reaction Unit of the TGA (2008) as well as the British Commission on Human Medi-
cines/Medicines and Healthcare products Regulatory Agency (2006) correspondingly state 
that the isolated cases which they have reported are “reports suggesting an interaction be-
tween warfarin and glucosamine”. The European Medicines Agency (EMEA) also assessed 
the known case reports similarly. In its assessment of a glucosamine-containing medicinal 
product (dosage 1250 mg glucosamine/day), the Agency reached the conclusion that “[n]o 
formal drug interaction studies have been performed with glucosamine-containing medicinal 
products. Therefore, a general caution was proposed to be included in the SPC. Pharma-
covigilance surveillance has resulted in some reports indicating a potential interaction with 
warfarin, and hence a warning has been added in the SPC text” (EMEA, 2006; Annex II). 
 
At present, the mechanism of an interaction between glucosamine and warfarin is still un-
clear (ADRAC/ADRU, 2008; Yue et al, 2006). In tests concerning the interaction of glucosa-
mine with coagulation mechanisms, it was observed that when glucosamine was adminis-
tered in in-vitro reaction batches, the aggregation of thrombocytes caused by ADP was inhib-
ited (Bertram et al., 1980; Hua et al., 2004; Lu-Suguro et al., 2005). The inhibition of ADP-
induced aggregation was also reported ex-vivo for thrombocytes of individuals who were 
given 1.5 g glucosamine/day over a period of seven days or for thrombocytes of guinea pigs 
when given high dosages of glucosamine (400 mg per animal and day) (Hua et al., 2004; Lu-
Suguro et al., 2005). However, the changes were not sufficient to influence the clinically rele-
vant parameters (bleeding time) that were examined in the study on guinea pigs mentioned 
above. The clinical relevance of these studies is still uncertain at present. 
 
BfR is not aware that the SPC (summary of product characteristics) or package leaflets on 
coumarin anticoagulants includes any special warnings stating that food supplements or 
foods and medicinal products containing additives of isolated glucosamine can amplify the 
effects. 
 
3.1.2 Dose-effect relationship 
 
Sufficient data necessary to deduce a dose-effect relationship in regard to possible interac-
tions of glucosamine and warfarin are not available. This is true for elevated INR levels ex-
pressing an interaction as well as for the severity of adverse effects which may be dose-
dependent and have ranged from changes in INR levels without symptoms all the way to life-
threatening haemorrhage. Only three case reports contained information on doses. In one 
case with elevated INR levels, the British Medicines and Healthcare products Regulatory 
Agency refers to a “suspected drug dose” of 1500 mg glucosamine, which corresponds to the 
daily dose (MHRA, 2007). In their case report, Rozenfeld et al. (2004) (elevated INR levels) 
cite a daily dose of 3 g glucosamine hydrochloride, 2.4 g chondroitin sulphate as well as an 
unspecified amount of manganese ascorbate. Kundsen und Sokol (2008) report an isolated 
case in which the dose increase from 1 g glucosamine hydrochloride and 800 mg chondroitin 
sulphate to 3 g glucosamine and 2.4 g chondroitin was related to increased INR levels (yet it 
cannot be ruled out that interactions already resulted from a low dose of glucosamine, which 
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was compensated through low doses of warfarin). In both of the cases named, the affected 
individuals also took various medicinal products/food supplements. The Australian AD-
RAC/ADRU report states that in one case, elevated INR levels were related to an increased, 
yet unspecified, dose of glucosamine (ADRAC/ADRU, 2008). The daily doses of glucosa-
mine are unspecified in other published case reports. Even when it is alleged that in the iso-
lated cases that have been published, doses of glucosamine which are common in medicinal 
products (about 1250-1500 mg glucosamine/day) or in some cases also higher doses were 
administered, these doses should be considered to be amounts that were able to cause ef-
fects, i.e. adverse interactions or amplify the effects of coumarin anticoagulants. The ques-
tion of the (highest) doses at which such effects are no longer observable would remain un-
answered. Coumarin anticoagulant therapy and the degree of intended inhibition of coagula-
tion depend on the ailment/condition that is to be treated. INR levels in the range of 2.0 – 4.0 
are aspired depending on the type of ailment, whereas recommendations in this regard are 
not standardised (Martindale, 2009). It is therefore possible that potential interactions not 
only depend on the dose of glucosamine, but also on the degree of individual anticoagulants 
therapy of each patient. 
 
It can be assumed that lower doses of glucosamine are connected with a lower probability 
and/or lower frequency and/or lower severity of the effect of an adverse interaction of gluco-
samine with coumarin anticoagulants. However, at the current state of knowledge it is not 
possible to deduce a dose that would be unlikely to increase the risk of occurrence of the 
above mentioned adverse interactions when taken on a regular basis, similar to a “tolerable 
upper intake level”. 
 
The fact that lower dosages of glucosamine than are common in medicinal products are not 
known to have caused reports of suspected health problems can also be related to the fact 
that there is no reporting systems for foods, which include food supplements, comparable to 
the pharmacovigilance that exist for medicinal products. Furthermore, a connection between 
possible health problems and an interaction with food supplements is probably not assumed 
due to the lack of awareness of the risk. 
 
3.1.3 Assessments by other committees  
 
In the pharmaceutical sector, EMEA has taken precautionary measures for a glucosamine-
containing medicinal product (as glucosamine hydrochloride) that is administered at a dose 
of 1250 mg glucosamine/day. The “Summary of Product Characteristics” contains the infor-
mation that “[d]ata on possible drug interactions with glucosamine is limited, but increased 
INR with coumarin anticoagulants (warfarin and acenocoumarol) has been reported. Patients 
treated with coumarin anticoagulants should therefore be monitored closely when initiating or 
ending glucosamine therapy” (EMEA, 2006, Annex III). In its report on possible interactions, 
the Australian Adverse Drug Reactions Advisory Committee and the Adverse Drug Reaction 
Unit of the TGA (2008) states that product information on warfarin-containing drugs includes 
the information that “there is some evidence that glucosamine might increase the activity of 
warfarin” and recommends that patients who take warfarin should check the coagulation time 
when they begin taking products of the “complementary medicine” category or when chang-
ing the dose (ADRAC/ADRU, 2008). In connection with the suspected cases described by 
the British Commission on Human Medicines/Medicines and Healthcare Products Regulatory 
Agency (2006), the Agency recommended that patients who are undergoing warfarin therapy 
should abstain from glucosamine. The French Food Safety Agency (AFSSA) and the Euro-
pean Food Safety Agency (EFSA) have assessed the use of glucosamine in food supple-
ments and for food fortification. These agencies did not note a relevant consumer risk of in-
teractions with coumarin anticoagulants for a dose of 500 or 750 mg glucosamine/day, i.e. 
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these assessments do not address possible interactions with coumarin anticoagulants (Af-
ssa, 2008; EFSA, 2009). The Canadian agency Health Canada’s publication on glucosamine 
as “Natural Health Product” (dosing ca. 1180-1662 mg) also provides no measures to protect 
individuals who take coumarin anticoagulants. Neither the publication text itself nor the re-
ferred scientific publications go into possible interactions with coumarin anticoagulants 
(Health Canada, 2008). 
 
3.1.4   Exposure 
 
The present risk assessment pertains to food supplements at daily intake amounts of 390-
790 mg isolated glucosamine. 
 
3.1.5   Risk characterisation  
 
Several reports have been published on possible interactions of glucosamine in isolated form 
and coumarin anticoagulants. The case reports should be taken as a clear indication of po-
tential interactions of glucosamine with coumarin anticoagulants. In this regard, BfR also re-
fers to conclusions of EMEA, whereby some reports that are part of pharmacovigilance sur-
veillance suggest a potential interaction with warfarin (EMEA, 2006; Annex II). The severity 
of observed effects ranged from INR changes without symptoms all the way to life-
threatening haemorrhage. Haemorrhage due to potential interactions can occur in nearly all 
organs, and it is safe to assume that the clinical indications, bodily symptoms and the degree 
of severity of the problem vary depending on the point of occurrence (e.g. gastrointestinal 
tract, brain) as well as on the extent of haemorrhage. In isolated cases severe adverse ef-
fects are possible. The number of people treated with coumarin anticoagulants in Germany 
alone comprises hundreds of thousands of people. In the United States, the number of pre-
scriptions for the anticoagulant warfarin for outpatient treatment rose from 21 million prescrip-
tions in 1998 to 30.6 million prescriptions in 2004 (Wysowski et al., 2007). 
 
For the majority of existing case reports of potential interactions, no information on the dos-
ages of glucosamine used is available. In those cases where such information is available, 
the dosages are clearly higher than the doses in question here, whereas one suspected case 
reports a dose of 1.5 g glucosamine/day (MHRA, 2007). However, the data available does 
not constitute a reliable basis for the identification of an “effect level”. Furthermore, the health 
assessment of potential interactions must consider additional factors such as interindividual 
variability, questions concerning the extrapolation of “effect level” on “no-effect level”, the 
quality of the data pool or adequate regard for sufficient safety margins. While it can be as-
sumed that lower doses of glucosamine are accompanied by a lower probability of the occur-
rence and/or lower frequency and/or lower severity of possible adverse interactions of gluco-
samine with coumarin anticoagulants, a dosage taken on a regular basis that bears an im-
probable risk of the occurrence of potential interactions of glucosamine with coumarin anti-
coagulants cannot be deduced based on the present state of knowledge. 
 
In light of the severity of possible health effects of potential interactions of glucosamine with 
coumarin anticoagulants and the frequency of prescription of warfarin, BfR deems measures 
that protect individuals who take coumarin anticoagulants necessary when isolated glucosa-
mine is used in food supplements in the amounts in question (393-786 mg glucosamine/day). 
Otherwise, individuals in this group are in danger of experiencing adverse interactions with 
coumarin anticoagulants.  
 
3.2   Individuals with a known risk of cardiovascular disease 
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In 2004, the Danish Medicines Agency (DKMA) reported that elevated cholesterol levels 
were observed in six patients who were given glucosamine. According to the Agency’s ac-
counts, the reports show that the cholesterol levels fell when glucosamine was discontinued 
and rose when glucosamine therapy was resumed. The Agency also reported that in clinical 
studies carried out before glucosamine was approved, increased cholesterol levels were not 
observed, that (however) no blood tests to determine the cholesterol levels or other lipids 
were carried out in any of the studies, and that these studies did not record increased choles-
terol levels as adverse effects (Danish Medicines Agency, 2004). In a follow-up report in 
2005, the Agency published provisional data of a study with 212 patients. Overall, no 
changes in blood cholesterol or lipid levels were observed in the comparison of glucosamine 
treatment (1.5 g glucosamine/day) with a placebo treatment. However, the Agency pointed 
out that only an analysis of the entire group of patients was available. It could thus not be 
ruled out that additional analyses might identify a subpopulation with elevated cholesterol 
levels. The Agency concluded that the latest information would not support the assumption 
that glucosamine treatment in general leads to elevated cholesterol levels, that available re-
ports show only few patients who are affected by elevated cholesterol levels, and that further 
analyses of the above mentioned data could determine the actual existence of a sensitive 
subpopulation. The Danish Medicines Agency recommended that the cholesterol levels of 
patients with known risk factors for cardiovascular diseases should continue to be checked 
before glucosamine treatment commences (Danish Medicines Agency, 2005). 
 
In the “Summary of Product Characteristics, Labelling and Package Leaflet” of the above 
mentioned glucosamine-containing medicinal product, EMEA stated that “[s]poradic, sponta-
neous cases of hypercholesterolaemia have been reported, but causality has not been es-
tablished”. However, in the subchapter “special warnings and precautions for use”, the 
Agency deemed it necessary to note that “[i]n patients with a known risk factor for cardiovas-
cular disease, monitoring of the blood lipid levels is recommended, since hypercholes-
terolemia has been observed in a few cases in patients treated with glucosamine” (EMEA, 
2006, Annex III). 
 
In more recent studies, Pham et al. (2007) observed an increase in triglycerides or LDL cho-
lesterol levels in some patients when they received 1500 mg glucosamine/day, yet no data is 
provided for this. In two additional clinical studies no significant changes in cholesterol levels 
were observed (Albert et al., 2007; Muniyappa et al., 2006). 
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